Cargando…
Role of OATP1B1 and OATP1B3 in Drug-Drug Interactions Mediated by Tyrosine Kinase Inhibitors
Failure to recognize important features of a drug’s pharmacokinetic characteristics is a key cause of inappropriate dose and schedule selection, and can lead to reduced efficacy and increased rate of adverse drug reactions requiring medical intervention. As oral chemotherapeutic agents, tyrosine kin...
Autores principales: | Garrison, Dominique A., Talebi, Zahra, Eisenmann, Eric D., Sparreboom, Alex, Baker, Sharyn D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7559291/ https://www.ncbi.nlm.nih.gov/pubmed/32916864 http://dx.doi.org/10.3390/pharmaceutics12090856 |
Ejemplares similares
-
Itraconazole-Induced Increases in Gilteritinib Exposure Are Mediated by CYP3A and OATP1B
por: Garrison, Dominique A., et al.
Publicado: (2022) -
Interaction of Antifungal Drugs with CYP3A- and OATP1B-Mediated Venetoclax Elimination
por: Eisenmann, Eric D., et al.
Publicado: (2022) -
Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro–in vivo correlations
por: Hu, S, et al.
Publicado: (2014) -
Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations
por: Hu, S, et al.
Publicado: (2017) -
A Metabolomics Approach for Predicting OATP1B-Type Transporter-Mediated Drug–Drug Interaction Liabilities
por: Li, Yang, et al.
Publicado: (2022)